How Many Adults with Private Health Insurance Could Use GLP-1 Drugs More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis
Long-term behavior & lifestyle integration An RD doesn't just focus on food
FAERS is a publicly available post-marketing safety surveillance database that contains adverse event reports, medication error reports, and product quality complaints reported by health professionals, pharmaceutical manufacturers, lawyers, and individual patients ( All reports between 1 January 2018 and 30 June 2022 were extracted for this analysis
Aim to follow your plan about 80-90% of the time, allowing for flexibility when life requires last-minute changes
However, these medications should complement, not replace, established lymphedema therapies like compression and manual drainage